07:00 , May 29, 2006 |  BC Week In Review  |  Company News

QLT, Advanced Ocular deal

QLT received an exclusive option to license AOS’s rapamycin-based technology to treat ophthalmic diseases. If QLT exercises the option, AOS will receive up to $3.5 million in option fees and milestones, plus royalties. QLT Inc....